Reductil vs Phentermine: How the Two Drugs Differed

If you search for older weight loss drugs, two names keep appearing side by side: Reductil (sibutramine) and phentermine. Both were prescribed to reduce appetite. Both raised heart rate and blood pressure in some users. Both were controlled substances in some countries. To many readers they look like near-twins.

They were not. They worked through different brain chemistry, were approved for different lengths of use, were backed by different kinds of evidence, and ended up with very different fates. One was withdrawn from the major regulated markets in 2010. The other is still prescribed today, with tighter limits and ongoing debate.

This guide compares the two side by side so you can see exactly where they overlapped and where they diverged. It is educational and does not replace medical advice, and it is not a recommendation to use either drug.

At a glance: the side-by-side table

Feature	Reductil / Meridia (sibutramine)	Phentermine
Drug class	Serotonin-noradrenaline reuptake inhibitor (with weak dopamine effect)	Sympathomimetic amine, structurally related to amphetamine
Main action	Blocks reabsorption of serotonin and noradrenaline in the brain, increasing fullness	Promotes release of noradrenaline (and to a lesser extent dopamine), reducing hunger
First approved	Late 1990s (U.S. approval in 1997)	1959 (U.S.)
Intended duration	Long-term (studied and used for a year or more)	Short-term, usually a few weeks under U.S. labeling
Typical form	Once-daily capsule (commonly 10 mg, with 15 mg as an option)	Once-daily tablets or capsules (for example 15 to 37.5 mg) or low-dose 8 mg tablets taken with meals
Active drug persistence	Parent drug cleared quickly, but active metabolites last roughly half a day or more	Half-life of about 20 hours
Typical average benefit in trials	Roughly a few kilograms beyond placebo over a year	About 3 to 4 kg beyond placebo in pooled short trials
Effect on blood pressure and pulse	Small average increases; some users had notable rises	Increases in some users; labeling urges caution
Large cardiovascular outcomes trial	Yes (SCOUT), which showed more non-fatal heart attack and stroke	No dedicated trial of this kind
Legal status in major markets	Withdrawn in 2010	Available by prescription in the U.S.; not approved in many other countries, including the UK
Controlled-substance status (U.S.)	Schedule IV	Schedule IV

Regulatory status varies by country and can change, so check your national medicines authority for the current position.

Part 1: How they work in the brain

Sibutramine: keeping the signal on longer

Nerve cells communicate by releasing chemical messengers and then reabsorbing them. Sibutramine, through its active breakdown products, blocked the reabsorption of serotonin and noradrenaline. With more of these messengers lingering, appetite-regulating circuits stayed active, and many people felt full sooner and ate less. The same mechanism put it in a family with certain antidepressants, which is why the drug was originally studied for depression. For background on that family, see our guide to SSRIs vs SNRIs.

Phentermine: releasing the signal

Phentermine acts more like a spark than a brake. It increases the release of noradrenaline from nerve endings, and to a smaller extent dopamine, switching on the body’s “fight or flight” system. Hunger fades, but the same activation can cause a faster heartbeat, restlessness, and poor sleep. Our explainer on what phentermine does to the body walks through those effects in detail.

Why the difference matters

• Serotonin involvement. Sibutramine’s serotonin effect created a risk of serotonin syndrome when combined with other serotonin-raising drugs. Phentermine’s labeling focuses instead on contraindications with MAO inhibitors and other stimulants.
• Mood effects. Because of its serotonin activity, sibutramine overlapped with antidepressant-type effects. Phentermine’s stimulant action more often causes nervousness and insomnia.
• Abuse profile. Both are controlled in the U.S., though phentermine’s amphetamine-like structure leads to additional caution in people with a history of substance misuse.

Part 2: How each drug was meant to be used

Reductil: a long-term plan

Sibutramine was designed for obesity treatment over months to years. Clinical trials ran for a year or longer, and the SCOUT trial followed participants for several years. Labeling advised stopping if a person did not lose a minimum amount of weight in the first few months, and urged regular checks of blood pressure and pulse.

Phentermine: a short course

U.S. labeling describes phentermine as a short-term adjunct, usually a few weeks, alongside a reduced-calorie diet and exercise. In practice, some clinicians prescribe it for longer under supervision, particularly in intermittent patterns or at lower doses, and observational data suggest this can be done in selected patients. It remains a debated area, and long-term use needs medical oversight. Our guide to realistic weight loss on phentermine reviews what the evidence shows, and regaining weight after phentermine covers what happens when treatment ends.

The “long-term” distinction

This difference is important. A drug intended for long-term use needs long-term safety evidence. Sibutramine was held to that standard, and SCOUT delivered it, with an unfavourable result. Phentermine’s short-term labeling has, in some ways, shielded it from the same demand, though it has also limited how it should be used.

Part 3: Effectiveness: what the numbers say

Direct head-to-head trials of the two drugs are scarce, so any comparison relies on separate studies with different designs. Treat these as ballpark figures.

Measure	Sibutramine	Phentermine
Typical average advantage over placebo	Around 3 to 5 kg at about 12 months in systematic reviews of trials	Around 3 to 4 kg in pooled analyses of short trials (2 to 24 weeks)
Study length	Many year-long trials	Mostly short; one classic 36-week study from the 1960s
Quality of evidence	More large, modern trials, including a multi-year outcomes trial	Older and smaller studies, with some newer observational data
Individual variation	Wide; some lost little, some lost more	Wide; some lost little, some lost more

The key point is that neither drug produced the double-digit average losses seen with newer injectable medicines. They sit at the modest end of the prescription spectrum. For a comparison with today’s options, see Wegovy alternatives and safer approved alternatives to Reductil for weight loss today.

Part 4: Safety: where the paths split

What they had in common

• Both can raise heart rate and, in some people, blood pressure.
• Both can cause dry mouth, constipation, insomnia, and nervousness.
• Both are unsuitable for people with established cardiovascular disease, uncontrolled hypertension, or certain rhythm disorders.
• Both carry interaction concerns, particularly with other drugs that act on brain chemistry.
• Neither should be used in pregnancy.

Where sibutramine’s story diverged

Sibutramine had a large, long, randomised outcomes trial. SCOUT enrolled nearly 10,000 older adults at high cardiovascular risk and found that the primary outcome (non-fatal heart attack, non-fatal stroke, resuscitated cardiac arrest, or cardiovascular death) occurred in about 11.4% of the sibutramine group versus about 10.0% of the placebo group. Deaths did not differ significantly, but the excess in non-fatal events was enough, combined with the modest weight benefit, to tip regulators toward withdrawal in 2010. We explain the numbers and the criticisms in the SCOUT trial explained, and the full regulatory sequence in why was Reductil withdrawn from the market?

Phentermine’s unanswered question

There is no equivalent trial for phentermine. That is not evidence of safety, and it is not evidence of harm. It is simply a gap. What we have instead is:

• Decades of clinical use, mostly short-term
• Labeling that lists cardiovascular disease and uncontrolled hypertension as contraindications
• Warnings, shared by the broader class of appetite-suppressing drugs, about pulmonary hypertension and valvular heart disease
• Observational data, such as a large electronic health record study, that did not detect a rise in cardiovascular events in selected users, but cannot prove cause and effect

Practically, this means phentermine should be treated with real caution, particularly in people with any cardiovascular risk. Our article on phentermine and caffeine shows how stimulant effects can stack, and is Adderall bad for your heart? discusses the wider question of stimulant-type drugs and cardiovascular risk.

Side-effect comparison

Effect	Sibutramine	Phentermine
Dry mouth	Common	Very common
Constipation	Common	Common
Insomnia	Common	Very common, especially with late dosing
Raised pulse or blood pressure	Documented, average increases small but variable	Documented; labeling advises caution
Nervousness or jitteriness	Occurred	Common
Headache	Common	Occurs
Serotonin syndrome risk with other serotonergic drugs	A recognised warning	Less central; MAO inhibitor contraindication is the key interaction
Long-term cardiovascular outcome data	Yes (negative signal in high-risk group)	Limited

Part 5: Who each drug was (or is) unsuitable for

Because of the overlap, the cautions look similar. The details differ.

Condition	Sibutramine	Phentermine
Coronary artery disease, previous heart attack, or stroke	Contraindicated	Contraindicated
Heart failure or serious arrhythmia	Contraindicated	Contraindicated
Uncontrolled high blood pressure	Contraindicated	Contraindicated
Taking MAO inhibitors (or within 14 days)	Contraindicated	Contraindicated
Taking SSRIs, SNRIs, or other serotonergic drugs	Serious interaction concern	Discuss with prescriber; caution advised
Hyperthyroidism	Caution	Contraindicated
Glaucoma	Caution (narrow-angle)	Contraindicated
History of drug misuse	Caution	Contraindicated under labeling
Pregnancy or breastfeeding	Not recommended	Not recommended

Sibutramine’s contraindications reflect its labeling before withdrawal, and phentermine’s reflect current U.S. prescribing information. If you are considering phentermine, review the current label on DailyMed and discuss it with a prescriber.

Part 6: Availability and legal status today

Sibutramine

Withdrawn in 2010 in the European Union, the United States, Canada, Australia, and many other countries. It is not a lawful prescription option in those markets. Any product sold as Reductil or sibutramine today should be treated as suspect. Worse, some supplements have been found to contain it secretly. We cover that danger in hidden sibutramine in herbal slimming pills.

Phentermine

Available by prescription in the United States in several forms and strengths. It is a Schedule IV controlled substance there. It is not approved in many other countries, including the UK, and regulations differ elsewhere. If you want to understand the product names, our comparison of phentermine vs Adipex explains brand versus generic. For the prescribing process, read how to get a phentermine prescription online, which also covers safe and unsafe sources.

Part 7: Why one survived and the other did not

This is the heart of the comparison, and it comes down to four factors.

1. Evidence that was gathered. Sibutramine was forced to prove long-term cardiovascular safety, and the answer was unfavourable. Phentermine was never asked the same question at scale.
2. Duration of intended use. A drug taken for years has more opportunities to cause cumulative harm than one taken for weeks.
3. Population. Sibutramine was marketed as a long-term obesity treatment for a broad population in which heart disease is common. Phentermine’s short-term framing keeps exposure shorter.
4. Risk-benefit at the time. Regulators judged that sibutramine’s modest benefit could not justify the observed risk. For phentermine, they continue to allow short-term use with restrictions, though some critics argue the evidence base is thin.

It would be a mistake to conclude that phentermine is therefore proven safe. The more accurate statement is that sibutramine was tested harder, and it failed the test, while phentermine has been tested less. For a related case of another withdrawn drug, see Belviq vs phentermine.

Part 8: The decision grid

Because sibutramine is no longer a lawful choice in major markets, this grid is less about choosing between the two and more about understanding which situations lead where. It is a general orientation, not personal advice.

Your situation	Sibutramine / Reductil	Phentermine	Practical direction
You have heart disease, past stroke, or an arrhythmia	Contraindicated (and unavailable)	Contraindicated	Neither. Ask a doctor about heart-safe weight management.
You have uncontrolled high blood pressure	Contraindicated	Contraindicated	Control blood pressure first. See natural ways to lower blood pressure and your doctor.
You take an antidepressant	Serious interaction risk	Needs prescriber review	Do not combine without medical advice.
You are otherwise healthy and want short-term support	Not available legally	May be considered by a prescriber in the U.S.	Discuss suitability, monitoring, and a maintenance plan with a clinician.
You are pregnant, planning pregnancy, or breastfeeding	Not recommended	Not recommended	Avoid both. Ask your doctor about safe nutrition support.
You found a “herbal” capsule promising Reductil-like results	May contain hidden sibutramine	May contain hidden drugs	Do not take. See our alert.
You want long-term medical weight management	Withdrawn	Labeled for short-term use	Review modern options in safer approved alternatives to Reductil and alternatives to phentermine.
You previously took Reductil and stopped	No special action usually needed	Not applicable	Mention it to your doctor and keep up routine health checks.

Part 9: What replaced both

The weight loss medicine landscape has moved on considerably. Today’s prescription options work through different mechanisms and, in some cases, have been tested in large cardiovascular outcome trials. They include:

• Combination oral drugs, such as naltrexone-bupropion (see Contrave vs phentermine and Adipex vs Contrave) and phentermine-topiramate (see phentermine vs topiramate).
• Fat-absorption blockers, such as orlistat.
• Injectable hormone-based drugs, such as semaglutide and tirzepatide, which produce larger average weight loss than the older oral drugs.

Each has its own side effects, costs, and suitability, which we cover in detail in safer approved alternatives to Reductil for weight loss today. Whichever route is right for you, medical supervision is part of the safety.

Part 10: Beyond the pill

It is worth remembering that no drug in this comparison did the work on its own. Trials of both paired medicine with diet and activity advice. The habits that sustain weight loss are the same regardless of drug:

• Regular, protein-rich meals and plenty of fibre. Our 7-day diet plan for weight loss offers a starting template.
• Consistent movement, even simple walking.
• Protected sleep. See the importance of sleep for health.
• A maintenance plan for when treatment ends, covered in regaining weight after phentermine.

Myths and facts

Myth	What the evidence shows
“Reductil and phentermine are the same drug.”	They are different drugs with different mechanisms, approvals, and evidence.
“Reductil was banned, so phentermine must be banned too.”	Phentermine remains available in the U.S. under prescription, though not in every country.
“Phentermine is proven safe because it has been around since 1959.”	Longevity is not the same as outcome-trial proof. Its labeling carries serious cautions.
“Reductil was withdrawn because it did not work.”	It produced modest weight loss. The decisive factor was increased non-fatal heart attack and stroke in a large trial.
“A herbal version of Reductil is a safe substitute.”	Some so-called herbal products have been found to contain undeclared sibutramine.
“If I was fine on Reductil, I will be fine on phentermine.”	Individual responses and risks differ. The drugs act differently.
“Either drug alone will give lasting weight loss.”	Both worked modestly and depended on lifestyle change. Regain after stopping is common.

Questions to ask your doctor

1. Given my heart health and blood pressure, is any appetite-suppressing drug appropriate for me?
2. Which of my current medicines could interact with it?
3. How much weight loss should I expect, and by when?
4. How will you monitor my pulse and blood pressure?
5. What is the plan if it does not work or I cannot tolerate it?
6. Would a newer option with outcome data suit me better?

Frequently asked questions

Is Reductil the same as phentermine?

No. Reductil is a brand name for sibutramine, which blocks reuptake of serotonin and noradrenaline. Phentermine mainly increases the release of noradrenaline. They are different drugs with different histories.

Which worked better for weight loss, Reductil or phentermine?

There are almost no direct head-to-head trials. Separate studies suggest similar modest average benefits, in the range of a few kilograms beyond placebo, with wide individual variation. Sibutramine’s benefit was assessed over longer periods.

Was phentermine also withdrawn?

No. Phentermine remains available by prescription in the United States, although it is not approved in some other countries. Its labeling restricts it to short-term use and lists important contraindications.

Why was Reductil withdrawn but not phentermine?

Sibutramine was tested in a large cardiovascular outcomes trial, SCOUT, which found more non-fatal heart attacks and strokes in high-risk users. Phentermine has not had a comparable trial, and it is meant only for short-term use. That does not prove it is risk-free.

Can I take phentermine if I took Reductil before?

Past use does not automatically rule you out, but you should tell your prescriber. They will consider your current health, blood pressure, and medicines.

Is it safe to buy Reductil online?

No. It is no longer legally supplied in major markets, and products sold online as Reductil or sibutramine are unregulated and may be counterfeit or contaminated.

Do both drugs raise blood pressure?

Both can raise heart rate and, in some people, blood pressure, which is why labeling warns against use in people with cardiovascular disease and uncontrolled hypertension.

Which is more addictive?

Both were classified as Schedule IV controlled substances in the U.S., indicating a lower potential for abuse than higher schedules but still requiring control. Phentermine’s amphetamine-like structure leads to extra caution in people with a history of substance misuse.

What are the safer alternatives today?

Several approved options exist, including combination oral drugs, fat-absorption blockers, and injectable hormone-based drugs. Suitability depends on your health history, so discuss them with a clinician. Our guide to safer approved alternatives to Reductil reviews them.

The bottom line

Reductil and phentermine looked alike on the pharmacy shelf but differed in nearly every way that mattered: how they worked, how long they were meant to be taken, how thoroughly they were tested, and how their stories ended. Sibutramine had a large, long safety trial that revealed a heart and stroke signal, and it was withdrawn. Phentermine remains available, but with a thinner evidence base and a short-term label that deserves respect.

The most useful takeaway is not “which one was better” but how to judge any weight loss drug: look at the long-term outcome data, be honest about your heart health, avoid mystery products, and keep a clinician involved from the first prescription to the maintenance plan.

Medical disclaimer: this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.

Sources and further reading

• U.S. FDA: Drug Safety Communication on Meridia (sibutramine)
• New England Journal of Medicine: Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects (SCOUT)
• MedlinePlus: Phentermine
• DailyMed: current phentermine prescribing information
• NIDDK: Prescription Medications to Treat Overweight and Obesity